LEVO-T (levothyroxine sodium)
LEVO-T (levothyroxine sodium) is a synthetic T4 hormone indicated as replacement therapy for primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated for pituitary thyrotropin (TSH) suppression as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. **Limitations of Use:** LEVO-T is not indicated for the suppression of benign thyroid nodules or nontoxic diffuse goiter in iodine-sufficient patients, nor is it indicated for hypothyroidism during the recovery phase of subacute thyroiditis.
How LEVO-T Works
Levothyroxine (T4) is a synthetic form of the endogenous hormone L-thyroxine. Thyroid hormones exert their physiologic effects by diffusing into the cell nucleus and binding to thyroid receptor proteins attached to DNA, thereby regulating gene transcription and the synthesis of messenger RNA and cytoplasmic proteins. Although LEVO-T provides T4, the majority of thyroid hormone activity is mediated by triiodothyronine (T3), which is primarily derived (approximately 80%) from T4 via deiodination in peripheral tissues.
Details
- Status
- Prescription
- First Approved
- 2002-03-01
- Routes
- ORAL
- Dosage Forms
- TABLET
LEVO-T Approval History
What LEVO-T Treats
2 indicationsLEVO-T is approved for 2 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypothyroidism
- Thyroid Cancer
LEVO-T Boxed Warning
NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levo-T, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anor...
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levo-T, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning Thyroid hormones, including Levo-T should not be used for the treatment of obesity or for weight loss. Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity (6, 10).
LEVO-T Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to LEVO-T
3 of 14FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
6 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06073665 DOT4 | 1R01AG081698-01, #853300 R01AG081698 | Ph 4 | recruiting | Dosing of LT4 in Older Individuals |
| NCT05228184 | 20US-T414 | Ph 4 | terminated | Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH) |
| NCT05823012 results posted | XP-8121-120 | Ph 2 | completed | Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism |
| NCT04878614 | IRB#20-002097 | Ph 4 | terminated | Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding |
| NCT03281083 | MRN-01-NAFLD-01 | Ph 2 | terminated | Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD) |
| NCT00921050 | EN_LC_P136 | Ph 2, Ph 3 | completed | Subclinical Hypothyroidism and Mind in the Elderly |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LEVO-T FDA Label Details
Indications & Usage
FDA Label (PDF)LEVO-T is indicated for the treatment of Hypothyroidism; Thyroid Cancer.
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levo-T, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective...
Track LEVO-T with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.